1. Cell Cycle/DNA Damage
    Epigenetics
  2. PARP

BSI-201 (Synonyms: Iniparib; NSC-746045; IND-71677)

Cat. No.: HY-12015 Purity: 99.65%
Handling Instructions

BSI-201 is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

For research use only. We do not sell to patients.

BSI-201 Chemical Structure

BSI-201 Chemical Structure

CAS No. : 160003-66-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 92 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
10 mg USD 84 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 300 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 420 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg USD 780 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
500 mg USD 1800 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

BSI-201 is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer.

IC50 & Target[3]

PARP1

 

In Vitro

BSI-201 nonselectively modifies cysteine-containing proteins in tumor cells[1]. BSI-201 (100 μM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1[2]. BSI-201 in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes[3].

Clinical Trial
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 3.4243 mL 17.1215 mL 34.2431 mL
5 mM 0.6849 mL 3.4243 mL 6.8486 mL
10 mM 0.3424 mL 1.7122 mL 3.4243 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[1]

For nine day cell proliferation assay, MDA-MB-436 and MDA-MB-231 cells are plated at 2000 and 500 cells/well respectively in a 96-well plate and treated with veliparib, cmpd-A, cmpd-C, BSI-201 or BSI-201-met at 0, 0.0001, 0.01,0.1, 1 or 10 μM for nine days. For five day cell proliferation assay, MDAMB-231 and MDA-MB-436 cells are plated at 1000 and 4000 cells/well respectively in a 96-well plate and treated with BSI-201 or BSI-201-met at 0. 0.1, 0.3, 1, 3 or 10 μM in the presence of 0, 1.8, 3.75, or 7.5 µM BSO for 5 days. DLD1+/+ and DLD1-/- cells are plated at 1000 cells/well in a 96-well plate and treated with TMZ at 0, 0.003, 0.01, 0.03, 0.1, 0.3 or 1 mM in the presence of 0, 0.005, 0.05, 0.5, or 5 µM veliparib, or BSI-201 for five days. After treatment, cell titer glow is carried out[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

292.03

Formula

C₇H₅IN₂O₃

CAS No.

160003-66-7

SMILES

O=C(C1=CC=C(C([N+]([O-])=O)=C1)I)N

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.65%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BSI-201
Cat. No.:
HY-12015
Quantity: